M. Iosifidis (Thessaloniki, GR)

OrthoBiology, Surgery Center OrthoBiology, Surgery Center

Presenter Of 1 Presentation

Podium Presentation Osteoarthritis

10.3.5 - Intra-articular knee injection of mesenchymal stem cells for degenerative osteoarthritis improved the knee function at 3-years follow up

Presentation Number
10.3.5
Presentation Topic
Osteoarthritis
Lecture Time
14:06 - 14:15
Session Type
Free Paper Session
Corresponding Author
Disclosure
No Significant Commercial Relationship

Abstract

Purpose

Numerous treatment options have been proposed for affecting the natural history of knee osteoarthritis. Intra-articular injection with adipose-derived mesenchymal stem cells (MSCs) is an alternative to conventional methods. The aim of this study is to present 3-year mid-term results and the safety profile of this treatment option.

Methods and Materials

Twenty patients (10 women - 10 men, mean age 56.82±9.3 years and mean BMI 26.7±3.5) with knee mild and moderate osteoarthritis (Kellgren-Lawrence I-III) were treated with one intra-articular knee injection with autologous culture-expanded adipose-derived MSCs. The patients were evaluated before the injection and in 3rd, 6th, 12th, 24th, and 36th month after the treatment. Four subscales (Pain, Symptoms, Activity in Daily Living and Quality of Life) of Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire were used. Adverse effects and patients’ satisfaction was also recorded. The repeated measures ANOVA was used (p<0.05).

Results

No complications and/or adverse events had been reported. The ANOVA results indicated significant change over time for all KOOS subscales (p < 0.001). Post hoc testing confirmed significant changes in the Pain subscale between all-time points of measurements (p<0.001 to p=0.024) except for the 2nd year to 3rd year. Post hoc testing confirmed significant changes in the Symptoms subscale between all-time points of measurements (p<0.001 to p=0.046) except for the 2nd year to 3rd year. The ADL subscale changed significantly in each time period after injection (p<0.001 to p=0.019). The ADL subscale did not change significantly between 6 months and 1 year but significant changes were found between 6 months and 2, 3 years (p<0.001). Post hoc testing confirmed significant changes in the QoL subscale between all-time points of measurements (p<0.001 to p=0.001).

Conclusion

Knee intra-articular injection of adipose-derived MSCs is a safe conservative treatment option for degenerative knee osteoarthritis, with promising mid-term results concerning the knee joint function and pain reduce.

Collapse

Meeting Participant of

Lord Byron - ICRS Meeting Room (20) ICRS Committee Meeting

Membership & Bylaws Committee

Session Type
ICRS Committee Meeting
Date
05.10.2019
Time
13:30 - 14:30
Location
Lord Byron - ICRS Meeting Room (20)